Suppr超能文献

双相抑郁中 N-甲基-D-天冬氨酸拮抗剂的家族性酒精依赖与抗抑郁反应。

Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.

机构信息

Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Program, Department of Health and Human Services, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

Bipolar Disord. 2012 Dec;14(8):880-7. doi: 10.1111/bdi.12003. Epub 2012 Sep 14.

Abstract

OBJECTIVES

Both ketamine and ethanol are N-methyl-d-aspartate (NMDA) receptor antagonists. Ketamine has rapid antidepressant properties in major depressive disorder (MDD) as well as bipolar depression. In individuals with MDD, a positive family history of alcohol dependence (FHP) was associated with greater improvement in depressive symptoms after ketamine administration compared to individuals whose family history of alcohol dependence was negative (FHN). This study investigated whether FHP influences ketamine's antidepressant and perceptual effects in individuals with bipolar depression.

METHODS

A post hoc analysis was conducted on 33 subjects with DSM-IV bipolar disorder (BD) type I or II depression pooled from two previously published studies. All subjects had undergone a double-blind, randomized, crossover trial of a single intravenous infusion of ketamine (0.5 mg/kg) combined with lithium or valproate therapy. Subjects were rated at baseline; at 40, 80, 120, and 230 min; and at days 1, 2, 3, 7, 10, and 14 post-infusion. The primary outcome measure was Montgomery-Åsberg Depression Rating Scale (MADRS) scores. Patients were categorized as FHP when they reported at least one first-degree relative with alcohol dependence. Measures of psychosis, dissociation, and dysphoria were also collected.

RESULTS

After ketamine infusion, subjects with FHP showed significantly greater improvement on MADRS scores than FHN subjects. In addition, patients with FHP had attenuated psychotomimetic and dissociative scores compared to FHN patients.

CONCLUSIONS

FHP appears to predict a more sustained antidepressant response to ketamine in individuals with BD. Family history of alcoholism may be an important consideration in the development of glutamatergic-based therapies for depression.

摘要

目的

氯胺酮和乙醇都是 N-甲基-D-天冬氨酸(NMDA)受体拮抗剂。氯胺酮在重度抑郁症(MDD)和双相抑郁症中具有快速抗抑郁作用。在 MDD 患者中,与家族中没有酒精依赖史(FHN)的患者相比,阳性家族酒精依赖史(FHP)与接受氯胺酮治疗后抑郁症状的改善更大相关。本研究旨在探讨 FHP 是否影响双相抑郁症患者中氯胺酮的抗抑郁和知觉效应。

方法

对来自两项先前发表的研究的 33 名 DSM-IV 双相障碍(BD)I 型或 II 型抑郁症患者进行了事后分析。所有患者均接受了单次静脉输注氯胺酮(0.5mg/kg)联合锂或丙戊酸盐治疗的双盲、随机、交叉试验。患者在基线时;在 40、80、120 和 230 分钟;以及在输注后第 1、2、3、7、10 和 14 天进行评分。主要结局测量指标为蒙哥马利-Åsberg 抑郁评定量表(MADRS)评分。当患者报告至少有一位一级亲属有酒精依赖时,将其归类为 FHP。还收集了精神病、分离和不适的测量值。

结果

在氯胺酮输注后,FHP 患者的 MADRS 评分显著改善,优于 FHN 患者。此外,与 FHN 患者相比,FHP 患者的精神病和分离评分减弱。

结论

FHP 似乎预测 BD 患者对氯胺酮的抗抑郁反应更持久。家族性酒精中毒史可能是开发谷氨酸能为基础的抑郁症治疗方法的重要考虑因素。

相似文献

3
Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
J Affect Disord. 2017 Jan 15;208:560-566. doi: 10.1016/j.jad.2016.10.026. Epub 2016 Oct 26.
4
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist.
Biol Psychiatry. 2009 Jan 15;65(2):181-4. doi: 10.1016/j.biopsych.2008.09.029. Epub 2008 Nov 8.
5
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Arch Gen Psychiatry. 2010 Aug;67(8):793-802. doi: 10.1001/archgenpsychiatry.2010.90.
6
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Biol Psychiatry. 2012 Jun 1;71(11):939-46. doi: 10.1016/j.biopsych.2011.12.010. Epub 2012 Jan 31.
7
Neural correlates of rapid antidepressant response to ketamine in bipolar disorder.
Bipolar Disord. 2014 Mar;16(2):119-28. doi: 10.1111/bdi.12118. Epub 2013 Sep 18.
9
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.
J Clin Psychiatry. 2009 Dec;70(12):1662-6. doi: 10.4088/JCP.08m04659. Epub 2009 Sep 8.
10
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Arch Gen Psychiatry. 2006 Aug;63(8):856-64. doi: 10.1001/archpsyc.63.8.856.

引用本文的文献

1
A computational model to characterize the time-course of response to rapid antidepressant therapies.
PLoS One. 2024 Feb 2;19(2):e0297708. doi: 10.1371/journal.pone.0297708. eCollection 2024.
2
Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression.
J Child Adolesc Psychopharmacol. 2024 Mar;34(2):73-79. doi: 10.1089/cap.2023.0047. Epub 2024 Jan 3.
3
Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis.
Psychopharmacology (Berl). 2021 Jul;238(7):1737-1752. doi: 10.1007/s00213-021-05825-8. Epub 2021 Mar 31.
4
Nitrous oxide as a putative novel dual-mechanism treatment for bipolar depression: Proof-of-concept study design and methodology.
Contemp Clin Trials Commun. 2020 Jun 23;19:100600. doi: 10.1016/j.conctc.2020.100600. eCollection 2020 Sep.
5
Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial.
Neuropsychopharmacology. 2020 Jan;45(2):319-326. doi: 10.1038/s41386-019-0536-z. Epub 2019 Oct 7.
6
Neurophysiological Correlates and Differential Drug Response in Subjects With a Family History of an Alcohol Use Disorder.
Chronic Stress (Thousand Oaks). 2019 Jan-Dec;3. doi: 10.1177/2470547019865267. Epub 2019 Aug 30.
7
Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
Int J Environ Res Public Health. 2018 Apr 17;15(4):771. doi: 10.3390/ijerph15040771.
9
Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies.
Biol Psychiatry. 2018 Jul 15;84(2):95-105. doi: 10.1016/j.biopsych.2017.08.025. Epub 2017 Sep 19.
10
Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
J Affect Disord. 2017 Jan 15;208:560-566. doi: 10.1016/j.jad.2016.10.026. Epub 2016 Oct 26.

本文引用的文献

1
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Biol Psychiatry. 2012 Jun 1;71(11):939-46. doi: 10.1016/j.biopsych.2011.12.010. Epub 2012 Jan 31.
2
Translational magnetic resonance spectroscopy reveals excessive central glutamate levels during alcohol withdrawal in humans and rats.
Biol Psychiatry. 2012 Jun 1;71(11):1015-21. doi: 10.1016/j.biopsych.2011.07.034. Epub 2011 Sep 10.
3
Glutamatergic modulators: the future of treating mood disorders?
Harv Rev Psychiatry. 2010 Sep-Oct;18(5):293-303. doi: 10.3109/10673229.2010.511059.
4
Glutamate plasticity in the drunken amygdala: the making of an anxious synapse.
Int Rev Neurobiol. 2010;91:205-33. doi: 10.1016/S0074-7742(10)91007-6.
5
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Arch Gen Psychiatry. 2010 Aug;67(8):793-802. doi: 10.1001/archgenpsychiatry.2010.90.
7
Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.
Neuropsychopharmacology. 2010 Feb;35(3):834-46. doi: 10.1038/npp.2009.191. Epub 2009 Dec 2.
8
Bipolar disorder comorbid with alcoholism: a 1H magnetic resonance spectroscopy study.
J Psychiatr Res. 2010 Apr;44(5):278-85. doi: 10.1016/j.jpsychires.2009.09.006. Epub 2009 Oct 8.
9
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist.
Biol Psychiatry. 2009 Jan 15;65(2):181-4. doi: 10.1016/j.biopsych.2008.09.029. Epub 2008 Nov 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验